Radio and PodcastLive Radio & PodcastsScience & Medicine
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations?
11th Annual Palm Beach Cancer Symposium (April 3-4, 2009 Hollywood, Florida)—Peter Goodwin interviews John Macdonald, Chief Medical Officer of Aptium Oncology in Los Angeles about his data on the relevance of KRAS tumor...
About This Episode
Colorectal Cancer: KRAS-Driven Selection Of Molecular Therapy Could Save Millions: Bevacizumab, Cetuximab, Panitumomab, or Combinations? is an episode from Oncology Times Broadcast News. 11th Annual Palm Beach Cancer Symposium (April 3-4, 2...
Podcast
This episode belongs to Oncology Times Broadcast News.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Sep 28, 2009, 00:03:39 long, audio available.
Related Episodes
Continue listening to more episodes from Oncology Times Broadcast News.
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome
Sep 28, 2009 - 00:07:19
For Early Breast Cancer, Switch to Aromatase Inhibitor after Tamoxifen Extends Survival
Sep 28, 2009 - 00:06:03
Bevacizumab Did Not Improve Disease-Free Survival In Adjuvant Therapy For Early Colon Cancer
Sep 28, 2009 - 00:09:05
"Promising Activity" Of Cetuximab In Patients With Advanced Biliary Cancer
Sep 28, 2009 - 00:02:18